Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — Q1 2023 Earnings Presentation
32 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2023
Slide 1: 1Q2023 Results Update
1Q2023 Results Update PT. PRODIA WIDYAHUSADA TBK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Corporate Overview
CORPORATE OVERVIEW
Slide 4: Performance Highlight in 1Q2023
Performance Highlight in 1Q2023 • 50 years experience in Clinical Lab IDR 517.8 Billion Industry since 1973 1Q2023 Revenue (-6.9% yoy), CAGR 5yrs (+6.7%) • Has the most recognized Brand in Indonesia >639K • Largest private independent clinical 1Q2023 Visit (-17.9% yoy), CAGR 5yrs (+1.3%) lab chain b
Slide 5: Extensive Milestone to Grow
Extensive Milestone to Grow ▪ Received SMK3 accreditation • Establishment of Prodia National Became the first and and OHSAS 2015 Referral Lab, the first Indonesian only lab in Indonesia to ▪ Opened the first green Became the first clinical lab clinic to receive SNI ISO 15189 laboratory in Indonesia
Slide 6: Extensive Milestone to Grow
Extensive Milestone to Grow 2017 2018 2019 2020 2021 2022 2023 Launched Next The first private lab New Test New Test New Test Focus on Quality Applied Generation Lab in Indonesia that Development from Development from Development Diagnostic: Lab Automation: & Genomics Lab: using fully Next-Gen Lab:
Slide 7: Experienced Management Team
Experienced Management Team With more than 20 years experience in delivering growth and innovation of Prodia Years of Years of Years of Years of Years of 50 Experience 50 Experience 39 Experience 48 Experience 31 Experience Gunawan Endang Joseph Fellipus Keri Keri Lestari Lestari Dandan Andi Wijaya
Slide 8: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public Public 57% 15% 28% Distributor for Contract Research, therapy Distributor for medical Research and banking of healthcare equipment Organization stem cell products PT Prodia Widyahusada Tbk Nationwide Outlet Network across Indonesia
Slide 9: Investment Highlight
INVESTMENT HIGHLIGHT
Slide 10: Largest Independent Labs Chain
Largest Independent Labs Chain Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2020 & 2021) (Billion IDR) 3YRS CAGR 3YRS CAGR 39.5% 37.9% 26.0% 33.1% 23.9% 27.8% 7,225 2020 2021 2,737 4,551 4,874 1,782 1,926 32.7% 29.0% Prodia Next 5 Players Combined Others 2019 2
Slide 11: Strong Operational Track Record
Strong Operational Track Record VISITS (in million) REVENUE (in IDR trillion) 2.18 2.8 CAGR 2.4% CAGR 8.3% 2.5 1.47 Prodia has generated continuous 2017 2018 2019 2020 2021 2022 2017 2018 2019 2020 2021 2022 revenue growth and increasing REVENUE PER VISIT (in IDR ‘000) EBITDA (in IDR Billion) number
Slide 12: Comprehensive Service Offering
Comprehensive Service Offering Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, offering the most General Medical Genomic Testing Check-Up Services Preventive Treatment comprehensive range of clinical lab tests in Indo
Slide 13: Scalable Hub & Spoke Business Model
Scalable Hub & Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Centralized information “Hub and spoke” model offers Prodia Clinical Labs, Prodia Referral with integrated IT Hospitals and Other Clinics scalable platform reducing Lab S
Slide 14: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the Introduced new tests, such as NIPT ProSafe, Amino work of more than 500 Marketing Acid Profile, Fatty Acid Profile, CArisk, DIArisk, Liquid and Laboratory Information biopsy EGFR Mutation, New Born Screening, 17OH Service pe
Slide 15: Pioneer in New Lab Testing; Digital Healthcare Platform
Pioneer in New Lab Testing Offer more than 3,000 type of testing, with referral Target to launch minimum 10 Partnership to NUH Singapore and Quest Diagnostic US new testing every year One of The Largest Digital Healthcare Platform Walk-in Apps Doctor Referral Apps One Stop Health Solution Apps Prodi
Slide 16: Market Overview & Growth Strategy
MARKET OVERVIEW & GROWTH > STRATEGY ma » \
Slide 17: 2023 Indonesia Economic Outlook
2023 Indonesia Economic Outlook Stay Resilient with Positive Growth Forecast 4.5% – 5.3% Indonesia’s GDP Growth Projection for 2023 GDP Growth Projection 2023 Indonesia World Indonesia’s Govt’ 4.5% - 5.3% 2.3% World Bank 4.8% 1.7% Organization for Economic Cooperation 4.7% 2.2% and Development (OECD
Slide 18: Indonesia's Healthcare Market
Indonesia’s Healthcare Market Focusing more on preventive treatment and with the opportunity to tap in digitalization As the COVID-19 cases began to decrease, The Ministry of Health has focusing its The development of Indonesia Digital Healthcare Market creates good opportunity budget allocation mor
Slide 19: Company's Growth Strategy
Company’s Growth Strategy Expand our presence and grow our Build new growth pillars network of outlets in both physical and digital channel in Indonesia Orchestrate highest quality health ecosystem and Upgrade existing clinical laboratories to leading digital health ecosystem in Indonesia provide wi
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Flow Pathology Cytometry Laboratory Laboratory Personalized Treatment and Prevention The Concept of P
Slide 21: Prodia's Impact to Community
Prodia's Impact to Community Prodia delivers impact through initiatives to achieve sustainable business growth in creating added value for stakeholders including shareholders, customers, medical personnel, regulators, the communities and the environment. This program contains our contribution in the
Slide 22: Business Update
BUSINESS. UPDATE
Slide 23: Deliver Solution for Customer Needs with Customer Centric Model
Deliver Solution for Customer Needs with Customer Centric Model • Routine, Esoteric, Genomic Tests • Wellness Package Professional Contact Centre • Disease Screening • Call Centre 1500-830 Package • Chat Whatshapp 0855-1500-830 • Chat bot TANIA (Tanya Prodia) • Prodia Mobile Customer can book and pa
Slide 24: New Apps Launching – U by Prodia
New Apps Launching – U by Prodia >41,000 downloaders Managed by PT Prodia Digital Indonesia, U by Prodia is a comprehensive digital health service to provide one-stop digital health solution for its customer. 19
Slide 25: Digital Diagnostic Partner for Doctor
Digital Diagnostic Partner for Doctor Giving effectiveness and easiness for Doctor in manage the patient’s health report Prodia Mobile for Doctor apps assist doctors to create testing referral to all Prodia’s Lab Services, provides live chat and manage their patient’s online health report. Launched
Slide 26: Outlet Development
Outlet Development 2016-2023 Outlet Development 259 283 292 287 267 259 276 285 2023 Outlet Development Target 2 5 7 4** 4** 4** 4** 4** 9 11 14 14 12 9 11 11 1-2 118 108 98 113 121 130 128 122 Clinical Labs 1 new clinical lab open in Grand Wisata Bekasi on Feb 2023 147 148 148 148 149 129 136 143 2
Slide 27: 1Q2023 Revenue (Unaudited)
1Q2023 Revenue (Unaudited) Revenue (Unaudited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion 2017 2018 2019 2020 FY17-FY22 CAGR +8.3% 1Q18-1Q23 CAGR + 13.2% 2021 2022 2023 2,652 ▪ Soft revenue performance in 1Q23 1Q22-1Q23 was impacted by 2,182 Growth : -6.9% fasting period and 1,873 n
Slide 28: Financial Update
FINANCIAL UPDATE
Slide 29: 1Q2023 Gross Profit & Net Income
1Q2023 Gross Profit & Net Income Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY17-FY22 CAGR +9.2% 1Q18-1Q23 CAGR +8.7% FY17-FY22 CAGR +19.8% 1Q18-1Q23 CAGR +17.1% Gross Profit Margin Net Income Margin 1Q22-1Q23 1,633 growth: -32.1% 1Q22-1Q23 623.2 growth: -7.3% 25.4% 1,327 23.5% 1,041
Slide 30: 1Q2023 COGS & OPEX
1Q2023 COGS & OPEX COGS (in IDR Billion) OPEX (in IDR Billion ) FY17-FY22 CAGR +6.9% 1Q18-1Q23 CAGR +6.5% FY17-FY22 CAGR +4.5% 1Q18-1Q23 CAGR +5.1% Opex to revenue COGS to revenue G&A Expense Direct Cost Marketing Expense Indirect Cost 146 42 46 50 1Q22-1Q23 46 30 growth: +9.3% 125 157 41 1Q22-1Q23
Slide 31: 1Q2023 Financial Summary
1Q2023 Financial Summary (in IDR Bn) 1Q2023 1Q2022 Change (in IDR Bn) 1Q2023 FY2022 Change Revenue 517.8 556.1 -6.9% Total Asset 2,734.8 2,854.6 -4.2% Gross Profit 308.1 332.4 -7.3% Total Equity 2,381.6 2,350.7 +1.3% EBIT 82.8 125.3 -33.9% EBT 90.6 132.7 -31.7% Net Income 71.4 105.2 -32.2% EPS 76.19
Slide 32: Thank You!
THANK YOU! For more Information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150 Jakarta 10430, Indonesia www.prodia.co.id
PT Prodia Widyahusada — Q1 2023 Earnings Presentation on 6ix